Melatonin therapy in patients with Alzheimer's disease

Abstract: Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobioti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cardinali, Daniel Pedro, Vigo, Daniel Eduardo, Olivar, Natividad, Vidal, María Florencia, Brusco, Luis I.
Formato: Artículo
Lenguaje:Inglés
Inglés
Publicado: MDPI AG 2019
Materias:
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/1647
Aporte de:
id I33-R139123456789-1647
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
Inglés
topic MELATONINA
ENFERMEDAD DE ALZHEIMER
ENVEJECIMIENTO
DETERIORO COGNITIVO LEVE
TRASTORNOS DE LA MEMORIA
spellingShingle MELATONINA
ENFERMEDAD DE ALZHEIMER
ENVEJECIMIENTO
DETERIORO COGNITIVO LEVE
TRASTORNOS DE LA MEMORIA
Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
Olivar, Natividad
Vidal, María Florencia
Brusco, Luis I.
Melatonin therapy in patients with Alzheimer's disease
topic_facet MELATONINA
ENFERMEDAD DE ALZHEIMER
ENVEJECIMIENTO
DETERIORO COGNITIVO LEVE
TRASTORNOS DE LA MEMORIA
description Abstract: Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD.
format Artículo
author Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
Olivar, Natividad
Vidal, María Florencia
Brusco, Luis I.
author_facet Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
Olivar, Natividad
Vidal, María Florencia
Brusco, Luis I.
author_sort Cardinali, Daniel Pedro
title Melatonin therapy in patients with Alzheimer's disease
title_short Melatonin therapy in patients with Alzheimer's disease
title_full Melatonin therapy in patients with Alzheimer's disease
title_fullStr Melatonin therapy in patients with Alzheimer's disease
title_full_unstemmed Melatonin therapy in patients with Alzheimer's disease
title_sort melatonin therapy in patients with alzheimer's disease
publisher MDPI AG
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/1647
work_keys_str_mv AT cardinalidanielpedro melatonintherapyinpatientswithalzheimersdisease
AT vigodanieleduardo melatonintherapyinpatientswithalzheimersdisease
AT olivarnatividad melatonintherapyinpatientswithalzheimersdisease
AT vidalmariaflorencia melatonintherapyinpatientswithalzheimersdisease
AT bruscoluisi melatonintherapyinpatientswithalzheimersdisease
bdutipo_str Repositorios
_version_ 1764820525771653121